Volume 5, Issue 8, Pages 6-7 (August 2010)
5 of 29
PREVIEW
FULL TEXT
FULL-TEXT PDF (596 KB)
CITATION ALERT
CITED BY
RELATED ARTICLES
EXPORT CITATION
EMAIL TO A COLLEAGUE
RIGHTS/PERMISSIONS
DOWNLOAD IMAGES
NEED REPRINTS?
BOOKMARK ARTICLE
STOCKHOLM — When European drug regulators called for a study to push the safety profile of the sympathomimetic weight-loss drug sibutramine to its limit, the drug failed the test.
From the International Congress on Obesity
PII: S1558-0164(10)70262-5
doi:10.1016/S1558-0164(10)70262-5
© 2010 Elsevier Inc. All rights reserved.
Copyright © 2012 Elsevier Inc. All rights reserved. | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
PREVIEW